August 07, 2017

Not intended for U.S. and UK Media

Bayer Receives EU Approval for Stivarga® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer

Approval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States for patients with HCC
Berlin, August 7, 2017 - Bayer today announced the European Commission (EC) has
granted marketing authorization for Stivarga® (regorafenib) for the treatment
of adult patients with HCC who have been previously treated with Nexavar®
(sorafenib). Stivarga is the first and only treatment that has demonstrated a
significant improvement in overall survival (OS) in second-line HCC. This marks
the third major approval in five months for Stivarga, with the product also
gaining approval in the U.S. and Japan for second-line treatment of HCC in
April and June, respectively.

"Until now, there was no effective second-line systemic treatment option for
liver cancer patients and their treating physicians in Europe. With the EU
approval of Stivarga in HCC, the outlook could significantly improve for
patients with HCC, as they have now for the first time, a treatment plan with
two approved therapies involving the use of Stivarga directly after Nexavar,"
said Dr. Jordi Bruix, lead investigator for the RESORCE trial, BCLC Group,
Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Spain.

The approval is based on data from the international, multicenter,
placebo-controlled Phase III RESORCE [REgorafenib after SORafenib in patients
with hepatoCEllular carcinoma; NCT 01774344] trial, which investigated patients
with HCC whose disease had progressed during treatment with Nexavar. In the
trial, regorafenib plus best supportive care (BSC) was shown to provide a
statistically significant and clinically meaningful improvement in OS versus
placebo plus BSC (10.6 vs. 7.8 months, respectively, (HR 0.63; 95% CI
0.50-0.79; p<0.0001)), which translates to a 37% reduction in the risk of death
over the trial period. Adverse events observed in the RESORCE trial were
generally consistent with the known safety profile of regorafenib. The most
common treatment-emergent adverse events were hand-foot skin reaction,
diarrhea, fatigue and hypertension.

"Liver cancer is often diagnosed late and difficult to treat, but the EU
approval of Stivarga for HCC marks the first treatment advance for patients in
nearly a decade. Bayer continues to support the liver cancer community and is
committed to ongoing research in the field, as well as continuing to pursue
additional regulatory filings for Stivarga across the world," said Robert
LaCaze, Executive Vice President and Head of the Oncology Strategic Business
Unit at Bayer.

Liver cancer is often more difficult to treat than other cancers with an annual
mortality rate of 48,000 in the EU. Globally, it is the second leading cause of
cancer-related deaths.

Additional regulatory filings for Stivarga in HCC are under review in other
countries around the world, including China. The product was approved in the
U.S. and Japan for second-line treatment of HCC in April and June,
respectively. Stivarga is already approved in more than 90 countries worldwide,
including the U.S., Japan, China and countries in the EU, for the treatment of
metastatic colorectal cancer. Stivarga is also approved in more than 80
countries globally, including the U.S., Japan, China and countries in the EU,
for the treatment of metastatic gastrointestinal stromal tumors.

About Hepatocellular Carcinoma

Hepatocellular carcinoma, or HCC, is the most common form of liver cancer
representing approximately 70-85 percent of liver cancer worldwide. Liver
cancer is the sixth most common cancer in the world and the second leading
cause of cancer-related deaths globally. More than 780,000 cases of liver
cancer are diagnosed worldwide each year (52,000 in the European Union, 501,000
in the Western Pacific region and 30,000 in the United States) and the
incidence rate is increasing. In 2012, approximately 746,000 people died of
liver cancer including approximately 48,000 in the European Union, 477,000 in
the Western Pacific region and 24,000 in the United States.

About Regorafenib (Stivarga®)

Regorafenib is an oral multi-kinase inhibitor that potently blocks multiple
protein kinases involved in tumor angiogenesis (VEGFR1, -2, -3, TIE2),
oncogenesis (KIT, RET, RAF-1, BRAF), metastasis (VEGFR3, PDGFR, FGFR) and tumor
immunity (CSF1R).

In the EU, Stivarga is indicated as monotherapy for the treatment of adult
patients with mCRC who have been previously treated with, or are not considered
candidates for, available therapies including fluoropyrimidine-based
chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy, as well as for the
treatment of adult patients with unresectable or metastatic GIST who progressed
on or are intolerant to prior treatment with imatinib and sunitinib, and for
the treatment of adult patients with HCC who have been previously treated with
sorafenib.

Regorafenib is a compound developed by Bayer. In 2011, Bayer entered into an
agreement with Onyx, now an Amgen subsidiary, under which Onyx receives a
royalty on all global net sales of regorafenib in oncology.

About Oncology at Bayer

Bayer is committed to delivering science for a better life by advancing a
portfolio of innovative cancer treatments. The oncology franchise at Bayer
currently includes three oncology products and several other compounds in
various stages of clinical development. Together, these products reflect the
company's approach to research, which prioritizes targets and pathways, with
the potential to impact the way that cancer is treated.


Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.


Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma
Find more information at www.bayerpharma.com.

Forward-looking statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.